Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease

Authors Franssen FME, Spruit MA, Wouters EFM

Published 26 September 2011 Volume 2011:6 Pages 493—501

DOI http://dx.doi.org/10.2147/COPD.S24443

Review by Single-blind

Peer reviewer comments 4

Frits ME Franssen1, Martijn A Spruit1, Emiel FM Wouters1,2
1Program Development Center, CIRO+, Center of Expertise for Chronic Organ Failure, Horn, The Netherlands; 2Department of Respiratory Medicine, Maastricht University Medical Center, Maastricht, The Netherlands

Background: Polypharmacy of respiratory medications is commonly observed in patients with chronic obstructive pulmonary disease (COPD). The aims of this study were to investigate determinants of polypharmacy and to study the consistency of actual respiratory drug use with current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in pulmonary rehabilitation candidates with COPD.
Methods: Data were extracted from the records of all patients with a diagnosis of COPD referred for pulmonary rehabilitation to CIRO+ between 2005 and 2009. Use of respiratory medications, self-reported COPD exacerbations, lung function, blood gases, exercise capacity, Medical Research Council (MRC) dyspnea grade, and St George’s Respiratory Questionnaire (SGRQ) were recorded as part of assessment of health status.
Results: In total, 1859 COPD patients of mean age (± standard deviation) 64.3 ± 9.7 years and with a forced expiratory volume in one second (FEV1) of 44.7% ± 18.2% were included. On average, patients used 3.5 ± 1.5 respiratory medications; this number increased with increasing GOLD stage, MRC score, and SGRQ scores. FEV1 (% predicted), SGRQ, and number of recent exacerbations were independent determinants of polypharmacy. Use of long-acting bronchodilators and inhaled corticosteroids was substantial and comparable in all GOLD stages. Use of corticosteroids was not restricted to patients with frequent exacerbations.
Conclusion: Polypharmacy of respiratory medications is common in COPD patients with persistent symptoms. In addition to severity of disease, health status is an independent predictor of polypharmacy. Actual drug use in COPD patients referred for pulmonary rehabilitation is partially inconsistent with current GOLD guidelines.

Keywords: chronic obstructive pulmonary disease, management, pharmacotherapy, polypharmacy, pulmonary rehabilitation, respiratory drug use

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Readers of this article also read:

Spirometry for patients in hospital and one month after admission with an acute exacerbation of COPD

Rea H, Kenealy T, Adair J, Robinson E, Sheridan N

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:527-532

Published Date: 14 October 2011

Delivery characteristics and patients’ handling of two single-dose dry-powder inhalers used in COPD

Chapman KR, Fogarty CM, Peckitt C, Lassen C, Jadayel D, Dederichs J, Dalvi M, Kramer B

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:353-363

Published Date: 23 June 2011

Hypertension, poor glycemic control, and microalbuminuria in Cuban Americans with type 2 diabetes

Gustavo G Zarini, Joel C Exebio, Deva Gundupalli, et al

International Journal of Nephrology and Renovascular Disease 2011, 4:35-40

Published Date: 3 March 2011

Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease

Alicia Lacoma, Cristina Prat, Felipe Andreo, et al

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:157-169

Published Date: 28 February 2011

Rhinosinusitis in COPD: symptoms, mucosal changes, nasal lavage cells and eicosanoids

Violetta M Piotrowska, Wojciech J Piotrowski, Zofia Kurmanowska, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:107-117

Published Date: 20 April 2010

Fat-free mass change after nutritional rehabilitation in weight losing COPD: role of insulin, C-reactive protein and tissue hypoxia

Simonetta Baldi, Roberto Aquilani, Gian Domenico Pinna, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:29-39

Published Date: 17 February 2010

Antibiotic treatment of exacerbations of COPD in general practice: long-term impact on healthrelated quality of life

Marc Miravitlles, Carles Llor, Jesús Molina, et al

International Journal of Chronic Obstructive Pulmonary Disease 2010, 5:11-19

Published Date: 15 January 2010